[{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cytisine","moa":"Nicotinic receptor alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cytisinicline Analogs","moa":"Nicotinic receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Lake Street Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film Coated Oral Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cytisine","moa":"Nicotinic receptor alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Lake Street Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Cytisine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Lake Street Capital","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Lake Street Capital"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Propel Bio Partners LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Cytisine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.12,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Propel Bio Partners LLC","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Propel Bio Partners LLC"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Cytisine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Silicon Valley Bank","highestDevelopmentStatusID":"14","companyTruncated":"Achieve Life Sciences \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Achieve Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cytisine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Achieve Life Sciences \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Achieve Life Sciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Cytisine (cytisinicline) is a plant-based alkaloid with binding affinity to the nicotinic acetylcholine receptor. It is being evaluated for the treatment of smoking cessation and nicotine dependence.

                          Brand Name : Cytisine

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 10, 2024

                          Lead Product(s) : Cytisine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Cytisine (cytisinicline) is a plant-based alkaloid with binding affinity to the nicotinic acetylcholine receptor. It is being evaluated for the treatment of smoking cessation and nicotine dependence.

                          Brand Name : Cytisine

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 31, 2024

                          Lead Product(s) : Cytisine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The proceeds will be used for global development and commercialization of cytisinicline, being developed for smoking cessation and nicotine dependence.

                          Brand Name : Cytisine

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 29, 2024

                          Lead Product(s) : Cytisine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Silicon Valley Bank

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor, being evaluated for the treatment of smoking cessation and nicotine dependence.

                          Brand Name : Cytisine

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 29, 2024

                          Lead Product(s) : Cytisine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Proceeds will support Cytisinicline, a plant-based alkaloid with high affinity for nicotinic receptors, for smoking cessation in adult smokers.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $60.0 million

                          February 29, 2024

                          Lead Product(s) : Cytisine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Propel Bio Partners LLC

                          Deal Size : $124.2 million

                          Deal Type : Private Placement

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is being evaluated for smoking cessation and nicotine dependence.

                          Brand Name : Cytisine

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 29, 2024

                          Lead Product(s) : Cytisine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The proceeds will fund product development, including cytisinicline, a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor believed to aid in treating nicotine addiction for smoking and e-cigarette cessation.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 25, 2023

                          Lead Product(s) : Cytisine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Lake Street Capital

                          Deal Size : $16.5 million

                          Deal Type : Public Offering

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Cytisine (cytisiniclin)e is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal sy...

                          Brand Name : Cytisine

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 23, 2023

                          Lead Product(s) : Cytisine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal sy...

                          Brand Name : Cytisine

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 20, 2023

                          Lead Product(s) : Cytisine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Cytisine (cytisinicline) is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation and reducing the severity of withdrawal sy...

                          Brand Name : Cytisine

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 29, 2023

                          Lead Product(s) : Cytisine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank